Foley Partner Jacqueline Wright Bonilla was quoted in an article that appeared in FDA Week on August 5, 2011 titled “Gene Patent Ruling’s Isolation v. Purification Distinction Could Impact Biotech.” Wright Bonilla discusses a federal court ruling on DNA patent eligibility that distinguishes between the terms isolation and purification. She states that the distinction is not clearly defined with regards to non-nucleic acid biologics and pharma molecules, adding that this distinction might be determined on a product-by-product basis and influence how attorneys draft their patent claims.
Related News
27 November 2024
In the News
Lawrence Kraus Describes Loper Bright's Impact on False Claims Cases
Foley & Lardner LLP partner Lawrence Kraus is quoted in the Relias Media article, "Loper Bright Starting to Affect False Claims Cases."
26 November 2024
In the News
David Rosen on FDA GLP-1 Legal Battle – 'It's a precedent in this area'
Foley & Lardner LLP partner David Rosen described the legal battle between compounding pharmacies and the U.S. Food and Drug Administration over GLP-1 drugs in the BioSpace article, "Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability."
26 November 2024
In the News
Sara Abarbanel and Jacqueline Hayduk Assess Best Practices for Employee Assistance Programs
Employee assistance programs have become an extremely common benefit offered by U.S. employers.